OpenEvidence, the Miami-based AI platform often described as “ChatGPT for doctors,” is reportedly considering raising $200 million at a $20 billion valuation. If confirmed, that would represent a nearly 6x increase from the company’s $3.5 billion valuation in July 2025, and a meaningful jump from the $12 billion it commanded just months ago.
A fundraising pace that makes venture capitalists dizzy
OpenEvidence has been on an absolute tear. The company raised approximately $700 million across several funding rounds in the past year alone. Its Series C in October 2025 brought in $200 million at a $6 billion valuation. Then, just three months later, a $250 million Series D pushed that number to $12 billion.
The investor roster reads like a who’s who of Silicon Valley and beyond: Thrive Capital, DST Global, Sequoia, Google Ventures, Nvidia, and, notably, Mayo Clinic.
What OpenEvidence actually does
